Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on June 15, 2021, to shareholders of record as of May 14, 2021. This decision reflects the company's commitment to returning value to its shareholders while continuing to focus on improving healthcare through innovative medical technologies across various fields including vascular access and anesthesia. Teleflex maintains a diverse portfolio aimed at meeting unmet clinical needs.
Teleflex announced its Q1 2021 results, reporting revenues of $633.9 million, a modest increase of 0.5% year-over-year. However, on a constant currency basis, revenues fell by 2.6%. The GAAP diluted EPS dropped 43.2% to $1.58, while adjusted diluted EPS rose by 5.5% to $2.87. The company raised its full-year revenue growth guidance but lowered its GAAP diluted EPS forecast. A restructuring plan is in place, expected to yield annual savings of $13 million to $16 million.
Teleflex (NYSE: TFX) announced that Liam Kelly, Chairman, President, and CEO, will speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 a.m. (ET). A live audio webcast and presentation slides will be accessible on the investor section of the Teleflex website.
Teleflex is dedicated to medical technologies that enhance health and quality of life, with a diverse portfolio in areas like vascular access and emergency medicine. More information can be found at teleflex.com.
Teleflex Incorporated (NYSE: TFX) will announce its first quarter 2021 financial results before the market opens on April 29, 2021. An investor conference call is scheduled for 8:00 a.m. (ET) on the same day, accessible via a live audio webcast. A replay will be available from 11:00 a.m. on April 29 until May 6, 2021. Teleflex provides medical technologies aimed at improving patient health, focusing on innovation in various medical fields.
Teleflex is set to participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 9:15 AM (ET). Jake Elguicze, Treasurer and Vice President of Investor Relations, will present at the event. Investors can access a live audio webcast and slides on the company's website. Teleflex specializes in medical technologies aimed at improving health outcomes across various fields, including vascular access and anesthesia. For additional details, visit www.teleflex.com.
Teleflex announced that over 250,000 patients worldwide have been treated with the UroLift® System, a minimally invasive procedure for benign prostatic hyperplasia (BPH). In the U.S., BPH affects more than 42 million men, with about 12 million receiving treatment. The UroLift System differs from traditional options by providing rapid recovery and maintaining sexual function. Recent data reveal improved patient experiences with lower catheterization rates and higher satisfaction levels. The UroLift System has become a standard of care in urology practices, underscoring its effectiveness.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on March 15, 2021. Shareholders on record as of March 5, 2021 will receive this dividend. Teleflex focuses on providing medical technologies aimed at improving health outcomes, with a diverse portfolio that includes vascular access, cardiology, anesthesia, and more. For further details about their offerings, visit teleflex.com.
Teleflex reported fourth quarter 2020 revenues of $711.2 million, a 4.4% increase year-over-year, with adjusted diluted EPS of $3.25, down 0.9%. Full-year revenues fell 2.2% to $2.537 billion, alongside a 27.6% drop in GAAP diluted EPS to $7.10. The company estimates the COVID-19 pandemic had a $61 million negative impact on fourth-quarter revenue and $281 million for the full year. Looking ahead, 2021 guidance projects 10-11.5% revenue growth and adjusted diluted EPS between $12.50 and $12.70.
Teleflex Incorporated (NYSE: TFX) announced the submission of a Biologics License Application (BLA) for its investigational freeze dried plasma (FDP) candidate to the FDA. This candidate, developed in collaboration with the U.S. Army Medical Materiel Development Activity, aims to enhance emergency medical responses to battlefield injuries. The application is eligible for priority review and accelerated approval, facilitating potential rapid availability. The FDP is not yet FDA-approved. The announcement underscores Teleflex's innovation focus in medical technologies.
Teleflex Incorporated (NYSE: TFX) will be represented by CEO Liam Kelly at the Barclays Global Healthcare Conference on March 9, 2021, at 10:55 am ET. A live audio webcast of the event will be accessible on the investor section of Teleflex's website, along with a presentation slide deck. Teleflex specializes in medical technologies aimed at enhancing health and quality of life through innovative solutions in various medical fields, including vascular access and emergency medicine. For more information, visit www.teleflex.com.
